Bayer's Comeback Narrative Faces Its First Hard Evidence Test

Bayer shares rally 76.95% as glyphosate ruling and CEO's DSO cost-cutting plan fuel optimism; H1 results due Aug 4.

For two years, Bayer was the stock institutional investors loved to hate — a cautionary tale of a megamerger gone wrong, buried under a mountain of US litigation. The shares languished as the Monsanto acquisition became shorthand for destroyed shareholder value. But heading into early August 2026, the script has flipped dramatically. The stock now trades at €48.14, having climbed 76.95 percent over twelve months, and the market is watching to see whether the operational reality can match the narrative.

The transformation story centers on CEO Bill Anderson, whose "Dynamic Shared Ownership" model — DSO for short — represents one of the most aggressive corporate overhauls in recent German industrial history. The concept is disarmingly simple in theory, brutal in execution: dismantle the bureaucratic layers that once required up to twelve management levels to sign off on decisions, and replace them with roughly 2,000 self-organizing teams. The stated target is €2 billion in annual savings, to be achieved by the end of 2026 at the latest. Investors have bought into the vision — the stock has added 30.07 percent since the start of the year, and the broader twelve-month advance has been powered by a combination of legal progress and this structural reinvention.

The legal front has been particularly pivotal. For years, glyphosate litigation hung over the company like a sword of Damocles, making any valuation exercise feel futile. That changed in June, when a landmark US Supreme Court ruling provided the clearest legal contours yet for capping the company's exposure. The decision has been a key catalyst for the rally, which has seen the shares more than double from last August's 52-week low. A scheduled August 19 hearing on the glyphosate class-action settlement will now test whether that legal de-escalation holds.

There is also fresh momentum in the pharma pipeline. The drug candidate Asundexian has delivered positive Phase III data and is now under priority review by the US FDA, with the European Medicines Agency also examining the compound. If approved, Asundexian could more than offset the looming patent expiries on blockbusters like Xarelto — giving the market a genuine growth story to pair with the cost-cutting narrative.

That combination makes Tuesday, August 4 — when Bayer releases its half-year results — the first real evidence point in months. The stakes are considerable. Analysts expect the company to reaffirm its full-year guidance, but the market's focus will be on Crop Science, where pricing pressure in the agricultural sector has raised questions about margin sustainability. With a 30-day annualized volatility of 61.62 percent, the stock is not for the faint-hearted; any nuance in the outlook could trigger outsized moves in either direction.

Technically, the setup remains constructive but not overheated. The relative strength index sits at 57.5 — elevated after a 4.72 percent gain in seven days, yet still below overbought territory. The share price holds 22.80 percent above its 200-day moving average, and the 50-day support level at €43.05 provides a reference point for bulls. The 52-week high of €53.86 remains within reach, and a convincing set of numbers could see the psychologically important €50 mark reclaimed on a sustainable basis. The company's market capitalization currently stands at €46.85 billion.

The rally has not been without its wobbles — the stock slipped 0.76 percent in the most recent session — but the broader trajectory is unmistakable. Bayer has shed its status as the DAX's perennial problem child and re-emerged as its most compelling turnaround play. Whether that transformation is durable, however, depends on what the half-year numbers reveal. The market has been buying a story; on August 4, it gets to check the facts.